相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association
Hassan Farhat et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Gemtuzumab Ozogamicin: Time to Resurrect?
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
Stefan Faderl et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Improved Outcome of Patients With Low- and Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML) in First Relapse With Gemtuzumab and Cytarabine Versus Cytarabine
Thomas Prebet et al.
CANCER (2011)
Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria
Raphael Itzykson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype
Katharina Wagner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study
P. Chevallier et al.
LEUKEMIA (2011)
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse
Saiko Kurosawa et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
Cecile Pautas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin
P. Chevallier et al.
LEUKEMIA (2010)
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
Farhad Ravandi et al.
LEUKEMIA RESEARCH (2010)
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features
Claudia Haferlach et al.
BLOOD (2009)
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
Roberto Stasi et al.
CANCER TREATMENT REVIEWS (2008)
Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+ Primary Resistant or Relapsed Acute Myeloid Leukemia
Patrice Chevallier et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly
Jacob Laubach et al.
ONCOLOGIST (2008)
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: Results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
Claude Gardin et al.
BLOOD (2007)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse
A Weltermann et al.
LEUKEMIA (2004)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
Y Alvarado et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
AM Tsimberidou et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia:: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse
LY Shih et al.
BLOOD (2002)
分享论文
